News

Clarivate Unveils Innovative Features in EndNote 2025

Clarivate Unveils Innovative Features in EndNote 2025

Leading the Way in Research Solutions

Clarivate Plc (NYSE: CLVT), renowned for its innovative approach, has recently launched EndNote 2025. This upgrade introduces AI-driven tools aimed at enhancing research efficiency, ensuring scholars and researchers can focus on what matters most: advancing knowledge.

Key Features of EndNote 2025

With EndNote 2025, Clarivate aims to empower users with a suite of modern features that simplify the arduous research process. These enhancements serve to save time, improve organization, and facilitate collaboration among researchers. The key improvements include:

Generative AI-Powered Insights

The new Key Takeaway feature utilizes generative AI to extract crucial insights from research papers. This tool helps researchers quickly grasp the essential takeaways, enhancing the speed of discovery in academic pursuits.

Streamlined Journal Matching

Another standout addition is the enhanced Find a Journal tool. This machine-learning feature integrated within the Cite While You Write tool aids researchers in identifying the most suitable journals for their work, aligning their submission strategies with target publications.

Citation Management Simplified

Citing sources can often be a tedious task, but the Cite from PDF feature allows users to effortlessly insert a highlighted quote along with its citation into their documents with just a click, significantly reducing time spent on formatting.

An Enhanced User Interface

EndNote 2025 also boasts a modernized summary panel redesign, providing users with a clear and organized view of their research records. This improvement includes configurable detail options, allowing customization according to individual user needs.

Comprehensive Reference Library

The application is further strengthened by new options for viewing articles from Web of Science that cite existing records. This makes it easier for researchers to curate a more extensive and relevant reference library.

Additionally, improvements to the Find Reference Updates and Find Full-Text functionalities have been made, allowing easier access to these tools from the record menu, thereby enhancing the overall user experience.

Future Enhancements on the Horizon

Looking ahead, EndNote has plans to unveil further AI features, including the EndNote Research Assistant, scheduled for release in late 2025. This new functionality is anticipated to further enrich the user experience, making the research process even more seamless.

Foundation in AI Technology

At the core of these advancements is Clarivate's Academic AI Platform, a robust framework that ensures consistent and accelerated deployment of AI features across all its solutions. This underlying technology allows Clarivate to continually innovate and bring cutting-edge tools to researchers.

About Clarivate

Clarivate is recognized as a leading global provider of transformative intelligence. It specializes in delivering enriched data, insights, and analytics alongside expert services across various sectors, including Academia, Intellectual Property, and Life Sciences. For further information, you can visit www.clarivate.com.

Frequently Asked Questions

What is EndNote 2025?

EndNote 2025 is the latest version of Clarivate's reference management tool, which introduces new features to enhance the research process.

What AI capabilities are included in EndNote 2025?

EndNote 2025 includes generative AI tools that help extract key insights, facilitate journal matching, and simplify citation management.

How does EndNote 2025 help researchers?

The new features in EndNote 2025 automate tedious tasks, allowing researchers to save time and enhance their overall productivity with their scholarly work.

When will additional features be available?

Clarivate plans to release more AI features, including the EndNote Research Assistant, later in 2025.

How can I learn more about Clarivate?

For more details about Clarivate's offerings and services, please visit their official website at www.clarivate.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading